Senior Leadership Team

We have assembled a world-class team that is committed to bringing new, life-changing medicines to the people who need them most.

Jodie Morrison

Chief Executive Officer

Jodie Morrison is the Chief Executive Officer of Cadent Therapeutics and is a member of Cadent’s Board of Directors. Ms. Morrison most recently served as interim Chief Executive Officer at Keryx Biopharmaceuticals, Inc.  Previously she served as President and Chief Executive Officer of Tokai Pharmaceuticals, Inc…

Read Jodie’s Bio

Michael Curtis, PhD

President and Head of Research and Development

Michael Curtis is the President of Cadent Therapeutics and is a member of Cadent’s Board of Directors with over 25 years of experience in bringing novel treatments to patients. Prior to joining Cadent, he was Senior Vice President of Product Development and Regulatory Affairs at Catabasis Pharmaceuticals…

Read Mike’s Bio

Tim Piser, PhD

Chief Scientific Officer

Tim Piser is the Chief Scientific Officer of Cadent Therapeutics and has passionately pursued the discovery and development of neuroscience therapeutics for almost two decades in big pharma and in biotech, most notably at AstraZeneca and FORUM Pharmaceuticals. There, he led neuropharmacology…

Read Tim’s Bio

Gregg Keaney, PhD

Vice President of Product Development

Gregg Keaney is the Vice President of Product Development at Cadent Therapeutics and leads CMC (Chemistry, Manufacturing, and Controls) development, Phase 1 clinical operations, and a broad range of interdisciplinary portfolio management activities. At Ataxion Therapeutics, Gregg led…

Read Gregg’s Bio

Minnie Mildwoff

Vice President of Regulatory Affairs and Quality Assurance

Minnie Mildwoff is the Head of Regulatory Affairs and Quality Assurance at Cadent and has 20 years of experience across a broad range of regulated products. She has worked in various biotech and pharmaceutical organizations, more recently Novartis and Biogen.  Minnie’s strength lies in her…

Read Minnie’s Bio

Nicole Luosey

Vice President of Strategic and Program Operations

Nicole Luosey is the Vice President of Strategic and Program Operations at Cadent Therapeutics. Ms. Luosey most recently was Vice President, Program Management at Syntimmune where she led investor activities and diligence and integration efforts of the acquisition by Alexion…

Read Nicole’s Bio

Rob Gaffey

Vice President of Finance and Administration

Rob Gaffey is Vice President of Finance and Administration at Cadent Therapeutics.  Mr. Gaffey was most recently Vice President of Finance and Corporate Controller at Merrimack Pharmaceuticals.  Previously he served as Vice President of Finance at Dimension Therapeutics where he played a lead role…

Read Rob’s Bio

John McBride

Chief Finance Officer

Meet the Team

Chi-Li Chen, PhD

Associate Director of CMC Development

Taylor Copeland, BS

HR Associate and Office Manager

Ed Christian, PhD

Executive Director of Translational Medicine

Nicole Del Vecchio, MS

Clinical Trial Manager

Noah Goodman

Executive Director of Business Development

Abhijit Kamerkar, MS

Senior Scientist of CMC Development

Richard Lin, PhD, MPH

Associate Director of Biostatistics and Data Management

Sam Malekiani, MS

Director of Drug Development

Liz Simpson, BS

Director of Clinical Operations

Amber Trzeciak, MS

Executive Assistant

Laura Victor, BA

Clinical Trial Associate

Join Our Team!

We’re looking for visionaries who want to join our fun and passionate team of people.  

View Our Open Positions

Board Members

  • Peter Barrett, PhD
    Atlas Venture

  • David Grayzel, MD
    Atlas Venture

  • Tim Anderson
    Cowen Healthcare Investments

  • James Bristol, PhD
    Independent

  • Mark McDade
    Qiming Venture Partners, US

  • Mike Curtis, PhD
    Cadent Therapeutics

  • Franz Hefti, PhD
    Independent

  • Jodie Morrison
    Cadent Therapeutics

Clinical Advisors: Spinocerebellar Ataxia

  • Jeremy Schmahmann, MD
    Founding Director, Massachusetts General Hospital Ataxia Unit
    Professor of Neurology, Harvard Medical School
  • Susan Perlman, MD
    Director, Ataxia Center and Director, Neurogenetics Clinical Trials
    UCLA

  • Vikram Shakkottai, MD, PhD
    Associate Professor
    University of Michigan

  • Sheng-Han Kuo, MD
    Assistant Professor
    Columbia University

Clinical Advisors: Essential Tremor

  • Dietrich Haubenberger, MHSc, MD
    Director, Clinical Trials Unit
    NINDS, NIH

  • Rodger J. Elble, MD, PhD
    Director, Parkinson Disease and Movement Disorders Clinic
    SIU Medicine

  • Elan D. Louis, MD, MS
    Chief, Division of Movement Disorders
    Yale University

  • Sheng-Han Kuo, MD
    Assistant Professor
    Columbia University

  • William Ondo, MD
    Director, Movement Disorders Clinic
    Methodist Neurological Institute

Clinical Advisors: Schizophrenia

  • Daniel C. Javitt, MD, PhD
    Director, Division of Experimental Therapeutics
    Columbia University Medical Center/
New York State Psychiatric Institute

  • John H. Krystal, MD
    Chair, Department of Psychiatry
    Yale University School of Medicine

  • Mark Corrigan, MD
    Chairman of the Board, BlackThorn Therapeutics

  • Mark Bear, PhD
    Picower Professor of Neuroscience
    MIT

  • Michael F. Green, PhD
    Distinguished Professor, Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA

Our Investors

We believe in a world that is free.

Without restraint or hesitation. One where our minds think big, where our bodies lead the way, and where we harness the passion and energy to discover new and exciting things.

We create breakthrough therapies for neurological and psychiatric conditions by restoring brain rhythms to natural harmony.

Contact Us